MX2023013139A - Compuesto ciclico que tiene accion inhibidora selectiva en el homologo del oncogen viral de sarcoma de rata kirsten (kras) por sobre los homologos del oncogen viral de sarcoma de rata harvey (hras) y de neuroblastoma (nras). - Google Patents

Compuesto ciclico que tiene accion inhibidora selectiva en el homologo del oncogen viral de sarcoma de rata kirsten (kras) por sobre los homologos del oncogen viral de sarcoma de rata harvey (hras) y de neuroblastoma (nras).

Info

Publication number
MX2023013139A
MX2023013139A MX2023013139A MX2023013139A MX2023013139A MX 2023013139 A MX2023013139 A MX 2023013139A MX 2023013139 A MX2023013139 A MX 2023013139A MX 2023013139 A MX2023013139 A MX 2023013139A MX 2023013139 A MX2023013139 A MX 2023013139A
Authority
MX
Mexico
Prior art keywords
kras
cyclic compound
hras
nras
compound
Prior art date
Application number
MX2023013139A
Other languages
English (en)
Spanish (es)
Inventor
Satoshi Hashimoto
Hatsuo Kawada
Koji Takano
Minoru Tamiya
Tomoya Kotake
Mirai Kage
Yuma Wakamiya
Ryuji Hayashi
Yuya Morita
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2023013139A publication Critical patent/MX2023013139A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023013139A 2021-05-07 2022-05-06 Compuesto ciclico que tiene accion inhibidora selectiva en el homologo del oncogen viral de sarcoma de rata kirsten (kras) por sobre los homologos del oncogen viral de sarcoma de rata harvey (hras) y de neuroblastoma (nras). MX2023013139A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079012 2021-05-07
PCT/JP2022/019544 WO2022234853A1 (ja) 2021-05-07 2022-05-06 Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物

Publications (1)

Publication Number Publication Date
MX2023013139A true MX2023013139A (es) 2023-11-28

Family

ID=83932768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013139A MX2023013139A (es) 2021-05-07 2022-05-06 Compuesto ciclico que tiene accion inhibidora selectiva en el homologo del oncogen viral de sarcoma de rata kirsten (kras) por sobre los homologos del oncogen viral de sarcoma de rata harvey (hras) y de neuroblastoma (nras).

Country Status (17)

Country Link
US (1) US20240158446A1 (https=)
EP (1) EP4309741A4 (https=)
JP (1) JPWO2022234853A1 (https=)
KR (1) KR20240005777A (https=)
CN (1) CN117279933A (https=)
AR (1) AR125796A1 (https=)
AU (1) AU2022268781A1 (https=)
BR (1) BR112023022755A2 (https=)
CA (1) CA3218182A1 (https=)
CL (1) CL2023003137A1 (https=)
CO (1) CO2023014807A2 (https=)
CR (1) CR20230572A (https=)
IL (1) IL307605A (https=)
MX (1) MX2023013139A (https=)
PE (1) PE20250071A1 (https=)
TW (1) TW202309063A (https=)
WO (1) WO2022234853A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202446781A (zh) 2011-12-28 2024-12-01 日商中外製藥股份有限公司 胜肽化合物之製造方法
EP4166664A1 (en) 2015-03-13 2023-04-19 Chugai Seiyaku Kabushiki Kaisha Modified aminoacyl-trna synthetase and use thereof
JP7187323B2 (ja) 2017-01-31 2022-12-12 中外製薬株式会社 無細胞翻訳系におけるペプチドの合成方法
KR20250007021A (ko) 2017-06-09 2025-01-13 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
EP4056580A4 (en) 2019-11-07 2023-12-06 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A PEPTIDE COMPOUND COMPRISING A STERICALLY HINDERED AMINO ACID
BR112022007535A2 (pt) 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
US12312379B2 (en) 2021-05-07 2025-05-27 Chugai Seiyaku Kabushiki Kaisha Methods for producing cyclic compounds comprising N-substituted amino acid residues
JP7823181B2 (ja) * 2022-05-06 2026-03-03 中外製薬株式会社 Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物
CN115385867A (zh) * 2022-09-19 2022-11-25 安徽普利药业有限公司 一种氨基酸及其类似物的成环反应与开环方法
TW202430537A (zh) * 2022-10-20 2024-08-01 日商中外製藥股份有限公司 環狀胜肽的結晶的製造方法
EP4603105A1 (en) * 2022-11-09 2025-08-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras
CN120659773A (zh) * 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
WO2024101386A1 (ja) * 2022-11-09 2024-05-16 中外製薬株式会社 Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物
WO2024195801A1 (ja) 2023-03-20 2024-09-26 中外製薬株式会社 環状ペプチドの共結晶の製造方法
TW202506168A (zh) 2023-04-19 2025-02-16 日商中外製藥股份有限公司 包含環狀胜肽化合物及界面活性劑之組合物
CN120936619A (zh) 2023-04-20 2025-11-11 中外制药株式会社 用于生产环肽化合物的方法
CN116655766B (zh) * 2023-04-23 2023-12-12 山东第一医科大学(山东省医学科学院) 一种订书肽及其制备方法和应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025162428A1 (en) * 2024-01-29 2025-08-07 Syneron Technology Co. Ltd. Cyclic peptide compounds and compositions as ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN118324664B (zh) * 2024-03-14 2026-04-07 四川鸿日医药科技有限公司 一种丝氨酸衍生物的制备方法
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026004834A1 (ja) * 2024-06-25 2026-01-02 中外製薬株式会社 固体分散体、及びそれを含む組成物
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026009920A1 (ja) * 2024-07-03 2026-01-08 中外製薬株式会社 環状ペプチドの精製法及び製造法
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
TW202446781A (zh) 2011-12-28 2024-12-01 日商中外製藥股份有限公司 胜肽化合物之製造方法
WO2015179438A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN110869544B (zh) 2017-06-09 2024-03-08 中外制药株式会社 膜透过性高的环状肽化合物及包含其的文库
KR20250007021A (ko) * 2017-06-09 2025-01-13 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
WO2020122182A1 (ja) * 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
BR112022007535A2 (pt) * 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras

Also Published As

Publication number Publication date
CL2023003137A1 (es) 2024-06-14
IL307605A (en) 2023-12-01
PE20250071A1 (es) 2025-01-13
CR20230572A (es) 2024-01-25
CA3218182A1 (en) 2022-11-10
AR125796A1 (es) 2023-08-16
TW202309063A (zh) 2023-03-01
JPWO2022234853A1 (https=) 2022-11-10
CN117279933A (zh) 2023-12-22
US20240158446A1 (en) 2024-05-16
EP4309741A1 (en) 2024-01-24
WO2022234853A1 (ja) 2022-11-10
KR20240005777A (ko) 2024-01-12
EP4309741A4 (en) 2025-05-14
BR112023022755A2 (pt) 2024-01-02
CO2023014807A2 (es) 2023-11-20
AU2022268781A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
CR20230572A (es) Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras
MX2024013352A (es) Compuesto ciclico que tiene accion inhibitoria selectiva del oncogen viral del sarcoma de rata de kirsten (kras) sobre el oncogen viral del sarcoma de rata de harvey (hras) y el oncogen viral del sarcoma de rata de neuroblastoma (nras)
TN2023000250A1 (en) Inhibiting ubiquitin-specific protease 1 (usp1)
ZA202208783B (en) Kras mutant protein inhibitors
EP4043478A4 (en) CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION
MX2025003398A (es) Nuevo compuesto tetraheterociclico
MX2022006609A (es) Compuesto de quinazolina que contiene anillo espiro.
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
MY206036A (en) Modified homoserine dehydrogenase and method for producing homoserine or l-amino acid derived from homoserine using the same
MY197889A (en) Microorganism producing l-amino acid and method for producing l-amino acid using the same
MY206118A (en) Process for the hydroformylation of olefins using pt and thixantphos
ZA202402071B (en) Lyse variant and method for producing l-arginine by using same
TN2022000028A1 (en) Process-scale synthesis of a plasma kallikrein inhibitor
MY203625A (en) MICROORGANISM FOR PRODUCING L-AMINO ACID WITH ENHANCED ACTIVITY OF a-GLUCOSIDASE AND METHOD FOR PRODUCING L-AMINO ACID USING THE SAME
PH12019501577A1 (en) Gene involved in synthesis of cyclic peptide compound, method for producing a cyclic peptide compound using the same, and transformant comprising the same
MX2022003974A (es) Sujeta cables.
MX2023004950A (es) Proceso para purificacion de pleuromutilinas.
ZA202408113B (en) Improved process for the manufacture of osimertinib
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
MX2021012690A (es) Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
MY209549A (en) Process for the preparation of diosmin
MX2021002847A (es) Metodo para produccion mejorada de isomalt.
CA224993S (en) Ornament hook
CA212928S (en) Necklace
MX2025006007A (es) Polipropilenos para fabricacion aditiva